Esophageal Candidiasis as Post-COVID Presentation

Christian Ospina*, Alberto Ángel, Felipe Ángel, Lázaro Arango

Gastroenterology program, Universidad de Caldas, Colombia, US.


Keywords
Esophageal candidiasis, COVID-19, Antifungal treatments.

Introduction
Esophageal candidiasis is characterized by white plaques on the mucosa, with an incidence of 0.3 to 5% in general population, with risk factors such as immunosuppression, elderly, chronic use of proton pump inhibitors (PPI), among others [1], so far there is little evidence of the association of COVID-19, therefore, we present the following case.

Case Presentation
Patient who was admitted for pneumonia by COVID-19, requiring management with steroids and antibiotics, in his convalescence with odynophagia and retrosternal pain, an esophagogastroduodenoscopy was performed, showing cotton-wool plaques in the esophagus suggestive of candidiasis, receiving nystatin-fluconazole with resolution of the condition. Now asymptomatic.

Discussion
Esophageal candidiasis is an infection associated with risk factors such as age > 55 years, chronic use of proton pump inhibitors, smokers and immunosuppression. Its diagnosis is clinical, endoscopic and histological; once diagnosed, it should receive antifungal treatment [2] to avoid complications such as necrosis and esophageal stenosis. Given the little known about the disease associated with COVID-19, in this case, immunosuppression and steroid use probably triggered the infectious disease.

References